

1. Basse, C., Morel, C., Callens, C., Pierron, G., Servois, V., Vincent-Salomon, A., Jobard, A., Alt, M., Ricci, F., Loirat, D., Sablin, M.-P., Bretagne, M., Saint-Ghislain, M., Hescot, S., Gonçalves, A., Tredan, O., Dubot, C., Gavoille, C., Delord, J.-P., Campone, M., Isambert, N., Belin, L., Bieche, I., Kamal, M., and Le Tourneau, C. **Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.** [JCO Precision Oncology](#). (2018).
2. Belin, L., Kamal, M., Mauborgne, C., Plancher, C., Mulot, F., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Ricci, F., Alt, M., Loirat, D., Sablin, M.-P., Paoletti, X., Servois, V., and Le Tourneau, C. **Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial.** [Ann. Oncol.](#) (2017).
3. Kamal, M., Tarcic, G., Dureau, S., Edelheit, O., Barbash, Z., Lecerf, C., Morel, C., Miron, B., Callens, C., Servant, N., Bieche, I., Vidne, M., and Tourneau, C.L. **Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.** [Molecular Oncology](#). (2018).
4. Moreira, A., Masliah-Planchon, J., Callens, C., Vacher, S., Lecerf, C., Frelaut, M., Borcoman, E., Torossian, N., Ricci, F., Hescot, S., Sablin, M.P., Tresca, P., Loirat, D., Melaabi, S., Trabelsi-Grati, O., Pierron, G., Gentien, D., Bernard, V., Vincent Salomon, A., Servant, N., Bieche, I., Le Tourneau, C., and Kamal, M. **Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.** [European Journal of Cancer](#). (2019).
5. Le Tourneau, C., Kamal, M., Tsimberidou, A.-M., Bedard, P., Pierron, G., Callens, C., Rouleau, E., Vincent-Salomon, A., Servant, N., Alt, M., Rouzier, R., Paoletti, X., Delattre, O., and Bièche, I. **Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.** [J. Natl. Cancer Inst.](#) (2016).
6. Desportes, E., Wagner, M., Kamal, M., Salomon, A.V., Denizaut, G., Pierron, G., Rouleau, E., Jouffroy, T., Le Tourneau, C., Paoletti, X., and Servois, V. **Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial.** [Oncotarget](#). (2016).
7. Le Tourneau, C., and Kurzrock, R. **Targeted therapies: What have we learned from SHIVA?** [Nat Rev Clin Oncol](#). (2016).
8. Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., Garrabey, J., Boursin, Y., Deloger, M., Fu, Y., Commo, F., Scott, V., Lacroix, L., Dieci, M.V., Kamal, M., Diéras, V., Gonçalves, A., Ferrero, J.-M., Romieu, G., Vanlemmens, L., Mouret Reynier, M.-A., Théry, J.-C., Le Du, F., Guiu, S., Dalenc, F., Clapissou, G., Bonnefoi, H., Jimenez, M., Le Tourneau, C., and André, F. **Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.** [PLoS Med](#). (2016).
9. Belin, L., Kamal, M., Mauborgne, C., Plancher, C., Mulot, F., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Ricci, F., Alt, M., Loirat, D., Sablin, M.-P., Paoletti, X., Servois, V., and Le Tourneau, C. **Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial.** [Ann. Oncol.](#) (2016).
10. Paoletti, X., Asselain, B., Kamal, M., Servant, N., Huppé, P., Bieche, I., and Le Tourneau, C. **Design and statistical principles of the SHIVA trial.** [Chin Clin Oncol](#). (2015).
11. Le Tourneau, C.L., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., Armanet, S., Servant, N., Bièche, I., Bernard, V., Gentien, D., Jezequel, P., Attignon, V., Boyault, S., Vincent-Salomon, A., Servois, V., Sablin, M.-P., Kamal, M., Paoletti, X., and SHIVA investigators **Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.** [Lancet Oncol](#). (2015).
12. Lebofsky, R., Decraene, C., Bernard, V., Kamal, M., Blin, A., Leroy, Q., Rio Frio, T., Pierron, G., Callens, C., Bieche, I., Saliou, A., Madic, J., Rouleau, E., Bidard, F.-C., Lantz, O., Stern, M.-H., Le Tourneau, C., and Pierga, J.-Y. **Circulating tumor DNA as a non-invasive substitute to**

- metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.** [Mol Oncol.](#) (2015).
13. Le Tourneau, C., Belin, L., Paoletti, X., Bièche, I., and Kamal, M. **Precision medicine: lessons learned from the SHIVA trial - Authors' reply.** [Lancet Oncol.](#) (2015).
 14. Wassef, M., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., Caron, M., Marangoni, E., Chavrier, P., Le Tourneau, C., Kamal, M., Pasmant, E., Vidaud, M., Servant, N., Reyat, F., Meseure, D., Vincent-Salomon, A., Fre, S., and Margueron, R. **Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.** [Genes Dev.](#) (2015).
 15. Servant, N., Roméjon, J., Gestraud, P., La Rosa, P., Lucotte, G., Lair, S., Bernard, V., Zeitouni, B., Coffin, F., Jules-Clément, G., Yvon, F., Lermine, A., Pouillet, P., Liva, S., Pook, S., Popova, T., Barette, C., Prud'homme, F., Dick, J.-G., Kamal, M., Le Tourneau, C., Barillot, E., and Hupé, P. **Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.** [Frontiers in Genetics.](#) (2014).
 16. Tourneau, C.L., Kamal, M., Alt, M., Verlingue, L., Servois, V., Sablin, M.-P., Servant, N., and Paoletti, X. **The spectrum of clinical trials aiming at personalizing medicine.** [Chinese Clinical Oncology.](#) (2014).
 17. Le Tourneau, C., Paoletti, X., Servant, N., Bièche, I., Gentien, D., Rio Frio, T., Vincent-Salomon, A., Servois, V., Romejon, J., Mariani, O., Bernard, V., Huppe, P., Pierron, G., Mulot, F., Callens, C., Wong, J., Mauborgne, C., Rouleau, E., Reyes, C., Henry, E., Leroy, Q., Gestraud, P., La Rosa, P., Escalup, L., Mitry, E., Trédan, O., Delord, J.-P., Campone, M., Goncalves, A., Isambert, N., Gavoille, C., and Kamal, M. **Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.** [British Journal of Cancer.](#) (2014).
 18. Boeva, V., Popova, T., Lienard, M., Toffoli, S., Kamal, M., Le Tourneau, C., Gentien, D., Servant, N., Gestraud, P., Rio Frio, T., Hupé, P., Barillot, E., and Laes, J.-F. **Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.** [Bioinformatics.](#) (2014).
 19. Le Tourneau, C., Kamal, M., Trédan, O., Delord, J.-P., Campone, M., Goncalves, A., Isambert, N., Conroy, T., Gentien, D., Vincent-Salomon, A., Pouliquen, A.-L., Servant, N., Stern, M.-H., Le Corroller, A.-G., Armanet, S., Rio Frio, T., and Paoletti, X. **Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.** [Targeted Oncology.](#) (2012).